HIV Infection
📧 Sign up to get email alerts when something new happens for HIV Infection.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-12-22FDA Approved: PREZISTA — Supplemental Application (Janssen Products LP)
FDA approved a supplemental application for Prezista (darunavir) submitted by Janssen Products LP.
-
FDA approval · 2020-12-22FDA Approved: PREZISTA — Supplemental Application (Janssen Products LP)
The FDA approved a supplemental application for Prezista (darunavir) submitted by Janssen Products LP. The approval expands Prezista's label…
-
FDA approval · 2020-12-22FDA Approved: SYMTUZA — Supplemental Application (Janssen Products LP)
FDA approved a supplemental application for Symtuza (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) from Janssen Products …
-
FDA approval · 2020-12-22FDA Approved: ABACAVIR, LAMIVUDINE AND ZIDOVUDINE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin's supplemental application for the fixed-dose combination Abacavir/lamivudine/zidovudine for HIV-1 infection.
-
FDA label_change · 2020-12-22FDA Approved: PREZCOBIX — Supplemental Application (Janssen Products, LP)
FDA approved a supplemental application for PrezcoBix (darunavir ethanolate and cobicistat) from Janssen Products, LP. This action updates t…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-12-17Clinical Trial Update: Studying Partial-agonists for Ethanol and Tobacco Elimination in Russians With HIV (St PETER HIV) [Phase 2, Phase 3]
Phase 2/3 trial evaluating partial-agonists to reduce ethanol and tobacco use in people with HIV; completed study.
-
CLINICAL_TRIALS trial_result · 2020-12-17Clinical Trial Update: AIDS 347: IL-6 Blockade in Treated HIV Infection [Phase 1, Phase 2]
AIDS 347 evaluated an interleukin-6 blockade in treated HIV infection in Phase 1 and Phase 2; the trial has completed and results have been …
-
CLINICAL_TRIALS trial_result · 2020-12-16Clinical Trial Update: Mobile-Based Application "MyChoices" [NA]
Clinical trial update for a mobile app study (MyChoices) completed with results posted; conditions include HIV, sexually transmitted disease…
-
CLINICAL_TRIALS trial_result · 2020-12-11Clinical Trial Update: Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV [Phase 2]
Phase 2 trial update exploring reversing tissue fibrosis to improve immune reconstitution in HIV.
-
FDA approval · 2020-12-09FDA Approved: ZIDOVUDINE — Supplemental Application (Aurobindo Pharma Limited)
The FDA granted a supplemental approval for Zidovudine (generic) manufactured by Aurobindo Pharma Limited under an ANDA.
-
CLINICAL_TRIALS trial_result · 2020-12-09Clinical Trial Update: Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults [Phase 1]
Phase 1 study evaluating safety, pharmacokinetics, and antiviral activity of lenacapavir given subcutaneously in HIV-1 infected adults has c…
-
CLINICAL_TRIALS trial_result · 2020-12-03Clinical Trial Update: MMF for HIV Reservoir Reduction [Phase 2]
Phase 2 trial investigating mycophenolate mofetil (MMF) for HIV reservoir reduction in people with HIV infection has completed with results …
-
CLINICAL_TRIALS trial_result · 2020-12-03Clinical Trial Update: Vicriviroc (SCH 417690) Treatment Protocol in Human Immunodeficiency Virus (HIV)-Infected Participants: A Rollover Study for ACTG Protocol A5211 (P04100) [Phase 2]
Phase 2 rollover study update for Vicriviroc (SCH 417690) in HIV-infected participants; completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-12-02Clinical Trial Update: Use of HIV Self-Test Kits to Increase Identification of HIV-Infected Individuals and Their Partners [NA]
A completed clinical trial evaluating the use of HIV self-test kits to identify HIV-infected individuals and their partners.
-
CLINICAL_TRIALS trial_result · 2020-12-01Clinical Trial Update: The Effect of Phenytoin on the Pharmacokinetics of Nevirapine and the Development of Nevirapine Resistance [Phase 2]
Phase 2 trial update examining how phenytoin affects nevirapine pharmacokinetics and potential nevirapine resistance.
-
CLINICAL_TRIALS trial_result · 2020-11-30Clinical Trial Update: Efficacy of Antifolates Against Malaria in HIV-infected Pregnant Women and the Emergence of Induced Resistance in Plasmodium Falciparum [Phase 3]
Phase 3 trial assessing antifolates for malaria in HIV-infected pregnant women and reporting emergence of induced resistance in Plasmodium f…
-
CLINICAL_TRIALS trial_result · 2020-11-25Clinical Trial Update: Acceptability and Feasibility of Unsupervised HIV Self-Testing Among Networks of Men [Phase 1, Phase 2]
Clinical trial update on the feasibility and acceptability of unsupervised HIV self-testing among networks of men, completed across Phase 1 …
-
FDA approval · 2020-11-24FDA Approved: ZIAGEN — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for Ziagen (abacavir sulfate) by ViiV Healthcare Company.
-
CLINICAL_TRIALS trial_result · 2020-11-24Clinical Trial Update: A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons [Phase 4]
A Phase 4 clinical trial studying suppression and treatment of genital herpes infection in HIV-infected individuals was terminated.
-
FDA approval · 2020-11-23FDA Approved: EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Cipla USA Inc.)
FDA approved a supplemental application for a fixed-dose combination antiretroviral drug containing efavirenz, emtricitabine, and tenofovir …
-
CLINICAL_TRIALS trial_result · 2020-11-18Clinical Trial Update: Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk [Phase 4]
Phase 4 trial assessing the impact of hormonal contraception on HIV acquisition and transmission risk has completed with results posted.
-
FDA approval · 2020-11-16FDA Approved: MYTESI — Supplemental Application (Napo Pharmaceuticals, Inc.)
FDA approved a supplemental application for Mytesi (crofelemer) submitted by Napo Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2020-11-12Clinical Trial Update: Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients [Phase 2]
Phase 2 pharmacokinetic and safety study evaluating once-daily raltegravir and atazanavir in HIV-1 infected patients has completed.
-
CLINICAL_TRIALS trial_result · 2020-11-09Clinical Trial Update: Autologous CD4 T-Cells in HIV (C34-CXCR4) [EARLY_Phase 1]
A Phase 1 trial evaluating autologous CD4 T-cells targeting CXCR4 (C34-CXCR4) in HIV is completed with results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-11-06Clinical Trial Update: Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone [Phase 2, Phase 3]
A clinical trial comparing 48 weeks versus 24 weeks of injectable extended-release naltrexone for opioid dependence with HIV risk, completed…